R&D 4.0: A New Approach to Digitized R&D to Achieve Better Time-to-Market and its Applications in Product Development

The pharmaceutical industry faces significant challenges in bringing new drugs to market due to the complexities of the R&D process. These challenges include high costs, lengthy development timelines, and a low success rate. In response to these challenges, a new approach to R&D has emerged: R&D 4.0.
R&D 4.0 leverages advanced technologies such as Deep Learning, Machine Learning, Artificial Intelligence, 3D Printing; among others, to streamline the drug development process and reduce time-to-market. In this webinar, join Procaps Group to explore the role of these technologies to improve the pharmaceutical development process. We will showcase real-world case studies performed, including the utilization of three-dimensional printing technology in the development of complex and customized drug delivery systems. Additionally, we will discuss how Deep Learning algorithms can estimate moisture levels in gelatin mass at different stages of the manufacturing process using spectral data. This approach provides real-time data to optimize the production process and ensure consistent quality. Furthermore, we will explain how Machine Learning algorithms, specifically the Pearson correlation coefficient, are being used to analyse the interaction of different excipients in drug formulations. This analysis helps in optimizing drug formulations to improve stability and efficacy. Explore with Procaps Group the exciting potential of R&D 4.0 as a leading Softgel CDMO/CMO.
Discussion topics

• To gain an understanding of R&D 4.0 in the pharmaceutical industry, including its key principles and how it can help reduce time-to-market
• To learn about the benefits and challenges of utilizing advanced technologies such as 3D printing, Deep Learning, and Machine Learning in pharmaceutical development
• To explore real-world examples from Procaps on how these technologies have been used in pharmaceutical R&D, including in the development of complex drug delivery systems and the optimization of drug formulations specifically in Softgel advanced technologies
• Get a deeper insight on who Procaps Group is and how as a leading Softgel CDMO/CMO is incorporating these trends and technologies to achieve better time-to-market for its partners around the world